Skip to main content

Julie A. Kreyenbuhl, PharmD, PhD

Academic Title:


Primary Appointment:



VA Annex, 735

Phone (Primary):


Phone (Secondary):




Education and Training

Dr. Kreyenbuhl received a Pharm.D. from Mercer University College of Pharmacy and Health Sciences in 1993 and a Ph.D. in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy in 1999. She completed a post-doctoral fellowship at the Maryland Psychiatric Research Center in 2000. 


Dr. Kreyenbuhl’s primary research interest is the pharmacoepidemiology of serious mental illness. She has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia, serving as a co-investigator on the first update and principal investigator of grants funded by the NIMH and the VA to support the second update of the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. In addition, Dr. Kreyenbuhl has expertise in the area of medication adherence and has received support from the Brain and Behavior Research Foundation to evaluate adherence to antipsychotic and oral hypoglycemic medications in individuals with schizophrenia and Type 2 diabetes. She is also interested in methods to improve screening for the metabolic side effects of antipsychotic medications. She has received grant funding from VA HSR&D to determine if providing computerized, personalized health information directly to veterans with serious mental illnesses on whether their care adheres to screening guidelines for metabolic side effects increases rates of screening and activates patients to discuss screening with their providers. She has also received grant funding from VA HSR&D to study how women Veterans with serious mental illnesses and their prescribers manage the metabolic side effects of psychotropic medications of which women are disproportionately affected. She is also the PI, Co-PI, or co-investigator on other funded efforts to study computer-technology based interventions for individuals with serious mental illnesses, including the development and testing of a Smartphone application for enhancing adherence to antipsychotic medications. Dr. Kreyenbuhl has authored or co-authored over 80 publications in peer-reviewed journals.

Research/Clinical Keywords

serious mental illness; health services research; pharmacoepidemiology

Highlighted Publications

Kreyenbuhl J, Record EJ, Himelhoch S, Charlotte M, Palmer-Bacon J, Dixon LB, Medoff DR, Li L. Development and Feasibility Testing of a Smartphone Intervention to Improve Adherence to Antipsychotic Medications. Clinical Schizophrenia & Related Psychoses 2016 Jul 25. [Epub ahead of print] PubMed PMID: 27454213.

Kreyenbuhl J, Dixon LB, Brown CH, Medoff DR, Klingaman EA, Fang L, Tapscott S, Walsh M. A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications.  Community Mental Health Journal 2016 Apr 9. [Epub ahead of print] PubMed PMID: 27061185.

Kreyenbuhl J, Medoff DR, McEvoy JP, Smith TE, Hackman A, Nossel IR, Dixon LB, Essock SM, Buchanan RW. The RAISE Connection Program: Psychopharmacological Treatment of People with a First Episode of Schizophrenia. Psychiatric Services; 2016 Jul 1:appips201500438. [Epub ahead of print] PubMed PMID: 27364816.

Kreyenbuhl J, Record EJ, Palmer-Bacon J. A Review of Behavioral Tailoring Strategies for Improving Medication Adherence in Serious Mental Illness. Dialogues in Clinical Neuroscience 2016 Jun;18(2):191-201.

Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB.  The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. Schizophr Bull 2010 Jan; 36(1):94-103.

Additional Publication Citations

Hack SM, Medoff DR, Brown CH, Fang L, Dixon LB, Klingaman EA, Park SG, Kreyenbuhl JA. Predictors of Patient Communication in Psychiatric Medication Encounters Among Veterans With Serious Mental Illnesses. Psychiatr Rehabil J. 2016 Jun; 39(2):183-6.

Record EJ, Medoff D, Dixon L, Klingaman E, Park S, Hack S, Brown C, Fang LJ, Kreyenbuhl J.  Access to and use of the internet among veterans with serious mental illness.  Community Mental Health Journal 2016; 52(2), 136-141.

Charlotte M, Schwartz E, Slade E, Medoff D, Li L, Dixon L, Kilbourne AM, Kreyenbuhl J.  Gender differences in mood stabilizer medications prescribed to veterans with serious mental illness. Journal of Affective Disorders2015; 188: 112-117.

Schwartz E, Charlotte M, Slade E, Medoff D, Li L, Dixon L, Kilbourne A, Kreyenbuhl J.  Gender Differences in Antipsychotics Prescribed to Veterans with Serious Mental Illness. General Hospital Psychiatry 2015; 37(4):347-51.

Klingaman EA, Medoff DR, Park SG, Brown CH, Fang L, Dixon LB, Hack S, Tapscott S, Walsh MB, Kreyenbuhl JA. Consumer satisfaction with psychiatric services: The role of shared decision-making and the therapeutic relationship. Psychiatric Rehabilitation Journal 2015; 38(3):242-8.

Essock SM, Nossel IR, McNamara K, Bennett ME, Buchanan RW, Kreyenbuhl JA, Mendon SJ, Goldman HH, Dixon LB. Practical Monitoring of Treatment Fidelity: Examples From a Team-Based Intervention for People With Early Psychosis. Psychiatr Services 2015 Jul;66(7):674-6.

Park SG, Derman M, Dixon LB, Brown CH, Klingaman EA, Fang LJ, Medoff DR, Kreyenbuhl J. Factors Associated With Shared Decision-Making Preferences Among Veterans With Serious Mental Illness. Psychiatric Services 2014; Dec 1;65(12):1409-13.

Long JA, Wang A, Medvedeva EL, Eisen SV, Gordon A, Kreyenbuhl J, Marcus SC. Glucose Control and Medication Adherence Among Veterans With Diabetes and Serious Mental Illness: Does Collocation of Primary Care and Mental Health Care Matter? Diabetes Care 2014 Aug; 37:1–7.

Aakre JM, Medoff DR, Dixon LB, Kreyenbuhl J. Beliefs about antipsychotic versus hypoglycemic medications among individuals with serious mental illness and type 2 diabetes. Patient Prefer Adherence 2012; 6:389-94.

Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, Dixon LB. Time to discontinuation of first- and second-generation antipsychotic  medications in the treatment of schizophrenia.  .  Schizophrenia Research 2011; 131(1-3):127-32.

Kreyenbuhl J, Leith J, Medoff DR, Fang L, Dickerson FB, Brown C, Goldberg RW, Potts W, Dixon LB. A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness.  Psychiatry Research 2011; 188: 109-114.

Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for Type 2 diabetes differ between individuals with versus without schizophrenia? Schizophrenia Bulletin 2010; 36(2): 428-435.


Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull 2010 Jan; 36(1):71-93.


Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J. The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements.  Schizophr Bull 2010 Jan; 36(1):48-70.

Kreyenbuhl J, Nossel IR, Dixon LB. Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care:  A review of the literature. Schizophrenia Bulletin 2009; 35 (4):696-703.


Kreyenbuhl J, Medoff DR, Seliger SL, Dixon LB. Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. Schizophrenia Research 2008; 101: 256-265.


Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M. Adding or switching antipsychotic medications in treatment-refractory schizophrenia.  Psychiatric Services 2007; 58(7): 983-990.


Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.  Antipsychotic polypharmacy in the VA Health System: Patient characteristics and treatment patterns. Psychiatric Services 2007; 58(4): 489-495.


Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, Wohlheiter K, Mittal LP, Dixon LB. Extent and management of cardiovascular risk factors in patients with Type 2 diabetes and serious mental illness.  Journal of Nervous and Mental Disease 2006; 194 (6): 404-410.


Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.  Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 2006 May; 84(1):90-99.

Lehman AF, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden L, Kreyenbuhl J. Evidence-based treatment for schizophrenia. Psychiatr Clin North Am 2003; 26(4): 939-54.